AU3009801A - Combinations of medicaments for treating viral diseases - Google Patents

Combinations of medicaments for treating viral diseases

Info

Publication number
AU3009801A
AU3009801A AU30098/01A AU3009801A AU3009801A AU 3009801 A AU3009801 A AU 3009801A AU 30098/01 A AU30098/01 A AU 30098/01A AU 3009801 A AU3009801 A AU 3009801A AU 3009801 A AU3009801 A AU 3009801A
Authority
AU
Australia
Prior art keywords
medicaments
combinations
viral diseases
treating viral
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU30098/01A
Inventor
Karl Deres
Siegfried Goldmann
Erwin Graef
Thomas Kramer
Ulrich Niewohner
Arnold Paessens
Karl-Heinz Schlemmer
Jurgen Stoltefuss
Olaf Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999162010 external-priority patent/DE19962010A1/en
Priority claimed from DE2000112259 external-priority patent/DE10012259A1/en
Application filed by Bayer AG filed Critical Bayer AG
Publication of AU3009801A publication Critical patent/AU3009801A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
AU30098/01A 1999-12-22 2000-12-12 Combinations of medicaments for treating viral diseases Abandoned AU3009801A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19962010 1999-12-22
DE1999162010 DE19962010A1 (en) 1999-12-22 1999-12-22 Antiviral combination based on dihydropyrimidine derivatives and non-dihydropyrimidine HBV antiviral agents, are useful for treatment of HBV infections
DE2000112259 DE10012259A1 (en) 2000-03-14 2000-03-14 Antiviral combination based on dihydropyrimidine derivatives and non-dihydropyrimidine HBV antiviral agents, are useful for treatment of HBV infections
DE10012259 2000-03-14
PCT/EP2000/012570 WO2001045712A1 (en) 1999-12-22 2000-12-12 Combinations of medicaments for treating viral diseases

Publications (1)

Publication Number Publication Date
AU3009801A true AU3009801A (en) 2001-07-03

Family

ID=26004825

Family Applications (1)

Application Number Title Priority Date Filing Date
AU30098/01A Abandoned AU3009801A (en) 1999-12-22 2000-12-12 Combinations of medicaments for treating viral diseases

Country Status (2)

Country Link
AU (1) AU3009801A (en)
WO (1) WO2001045712A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2443703C2 (en) 2007-06-18 2012-02-27 Саншайн Лейк Фарма Ко., Лтд Bromophenyl substituted thiazolyl dihydropyrimidines
EA026977B1 (en) * 2012-01-06 2017-06-30 Янссен Сайенсиз Айрлэнд Юси 4,4-disubstituted 1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis b
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
PE20150776A1 (en) 2012-09-10 2015-05-21 Hoffmann La Roche 6-AMINO ACID-HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION
ES2792848T3 (en) 2014-02-05 2020-11-12 Novira Therapeutics Inc Combination therapy for the treatment of HBV infections
BR112016028000B1 (en) * 2014-05-30 2022-05-17 Qilu Pharmaceutical Co., Ltd Loop derivative of dihydropyrimide as an hbv inhibitor
CN105153164B (en) * 2014-05-30 2018-10-30 齐鲁制药有限公司 Dihydro-pyrimidin and ring derivatives as HBV inhibitor
JP6668468B2 (en) * 2015-11-03 2020-03-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Combination therapy of HBV capsid assembly inhibitor and interferon
WO2017108630A1 (en) * 2015-12-21 2017-06-29 F. Hoffmann-La Roche Ag Combination therapy of an hbsag inhibitor and an hbv capsid assembly inhibitor
EP3645516A4 (en) 2017-06-27 2021-07-07 Janssen Pharmaceutica NV Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections
SG11202003700TA (en) 2017-11-02 2020-05-28 Aicuris Gmbh & Co Kg Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
SG11202003746UA (en) 2017-11-02 2020-05-28 Aicuris Gmbh & Co Kg Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
EP3790866A4 (en) * 2018-05-08 2022-03-02 Janssen Sciences Ireland Unlimited Company Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases
US11053235B2 (en) 2018-08-09 2021-07-06 Janssen Sciences Ireland Unlimited Company Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
UY38435A (en) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg NEW UREA 6,7-DIHIDRO-4H-PIRAZOL [1,5-A] PIRAZINAS ACTIVE AGAINST THE VIRUS OF HEPATITIS B (HBV)
AR117189A1 (en) 2018-11-02 2021-07-21 Aicuris Gmbh & Co Kg DERIVATIVES OF 6,7-DIHIDRO-4H-PIRAZOLO [1,5-A] PIRAZIN INDOL-2-CARBOXAMIDAS ACTIVE AGAINST THE VIRUS OF HEPATITIS B (HBV)
UY38436A (en) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg NEW 6,7-DIHYDRO-4H-PYRAZOLE [1,5-A] PYRAZININDOL-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)
JP2022506351A (en) 2018-11-02 2022-01-17 アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト A novel urea 6,7-dihydro-4H-thiazolo [5,4-C] pyridine with activity against hepatitis B virus (HBV)
UY38439A (en) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg NOVELTY UREA 6,7-DIHYDRO-4H-PYRAZOLE [4,3-C] PYRIDINES ACTIVE AGAINST THE VIRUS OF HEPATITIS B (HBV)
AR117188A1 (en) 2018-11-02 2021-07-21 Aicuris Gmbh & Co Kg DERIVATIVES OF UREA 6,7-DIHIDRO-4H-PIRAZOLO [1,5-A] PYRAZINES ACTIVE AGAINST THE VIRUS OF HEPATITIS B (HBV)
CA3138380A1 (en) 2019-04-30 2020-11-05 Aicuris Gmbh & Co. Kg Novel oxalyl piperazines active against the hepatitis b virus (hbv)
AU2020265392A1 (en) 2019-04-30 2021-12-23 Aicuris Gmbh & Co. Kg Novel indolizine-2-carboxamides active against the hepatitis B virus (HBV)
CU20210089A7 (en) 2019-04-30 2022-06-06 Aicuris Gmbh & Co Kg COMPOUNDS DERIVED FROM PHENYL AND PYRIDYL UREAS ACTIVE AGAINST HEPATITIS B VIRUS (HBV)
CA3138643A1 (en) 2019-04-30 2020-11-05 Aicuris Gmbh & Co. Kg Novel indole-2-carboxamides active against the hepatitis b virus (hbv)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059418A (en) * 1989-09-20 1991-10-22 The Administrators Of The Tulane Educational Fund Synergistic effect of human recombinant interferon-beta on halogenated pyrimidines
WO1998033501A1 (en) * 1997-01-31 1998-08-06 Avid Therapeutics Inc. 2-benzoylamino-3-phenylpropenamide derivatives and methods of using the same
DE19817262A1 (en) * 1998-04-18 1999-10-21 Bayer Ag New dihydropyrimidine derivatives and their corresponding mesomers useful in treatment of hepatitis
DE19817264A1 (en) * 1998-04-18 1999-10-21 Bayer Ag New dihydropyrimidine derivatives and their corresponding mesomers useful as antiviral agents
DE19817265A1 (en) * 1998-04-18 1999-10-21 Bayer Ag Treating hepatitis B using new or known dihydropyrimidine derivative antiviral agents

Also Published As

Publication number Publication date
WO2001045712A8 (en) 2001-09-13
WO2001045712A1 (en) 2001-06-28

Similar Documents

Publication Publication Date Title
AU3009801A (en) Combinations of medicaments for treating viral diseases
AU2001244188A1 (en) Medicaments against viral diseases
AU3891299A (en) Combination therapy for treatment of depression
AU2001276860A1 (en) Medicaments for chemotherapeutic treatment of disease
IL154875A0 (en) Pyrazole derivatives for the treatment of viral diseases
AU7622000A (en) Compounds for the treatment of viral-mediated diseases
AU2000265525A1 (en) Medicament for treating intestinal diseases
AU7731700A (en) Low dose ifn-gamma for treatment of disease
AU2281601A (en) Treatment of viral infections using levovirinTM
AU2002322082A1 (en) Pharmaceutical composition for the treatment of viral infection
AUPQ232599A0 (en) Drug for treating fractures
AU3684395A (en) Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases
AU4215499A (en) Treatment of neurodegenerative diseases
AU3004000A (en) Methods for the treatment of apolipoprotein e related diseases
AU3760900A (en) Treatment of menstrual function
AU7449698A (en) Therapeutic agents for respiratory diseases
AU4145999A (en) Topical drug for the treatment of viral infections
AU1405001A (en) Treatment of diseases
AUPQ367699A0 (en) Treatment of cancer
AU5552400A (en) Treatment of cancer
IL151188A0 (en) Medicament for viral diseases
GB0028484D0 (en) Imidazolone derivatives for the treatment of viral diseases
AU3501100A (en) Synergistic combination for treatment of viral-mediated diseases
AU1618901A (en) Treatment of rosacea
AU5611701A (en) Agent for the diagnosis and therapy of viral diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase